


PRODUCT INFORMATION



Dolutegravir Item No. 22191

CAS Registry No.: 1051375-16-6
Formal Name: (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
Synonyms: GSK1349572, S/GSK1349572

MF: C₂₀H₁₉F₂N₃O₅
FW: 419.4
Purity: ≥98%
UV/Vis.: λ_{max}: 259 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Dolutegravir is supplied as a crystalline solid. A stock solution may be made by dissolving the dolutegravir in the solvent of choice. Dolutegravir is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. Dolutegravir has a solubility of 2.5 and 5 mg/ml in DMSO and DMF, respectively. Dolutegravir is also slightly soluble in ethanol.

Dolutegravir is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, dolutegravir should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Dolutegravir has a solubility of approximately 0.20 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Dolutegravir is a potent inhibitor of HIV integrase with an IC₅₀ value of 2.7 nM for HIV-1 integrase-catalyzed strand transfer *in vitro*.¹ It inhibits HIV-1 viral replication (EC₅₀ = 0.51 nM) in peripheral blood mononuclear cells (PBMCs). The cytotoxic concentration (CC₅₀) values for dolutegravir in unstimulated and stimulated PBMCs are 189 and 52 μM, respectively, resulting in a therapeutic index of at least 9,400. It prevents replication of several HIV-1 strains (EC₅₀s = 0.36-2.1 nM) that are resistant to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors and impairs their ability to infect CIP4 cells.^{1,2} Formulations containing dolutegravir have been used to treat HIV-1 infection in humans.³

References

1. Kobayashi, M., Yoshinaga, T., Seki, T., *et al.* *In vitro* antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. *Antimicrob. Agents and Chemother.* **55**(2), 813-821 (2011).
2. Hare, S.A., Smith, S.J., Métifiot, M., *et al.* Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). *Mol. Pharmacol.* **80**(4), 565-572 (2011).
3. Venter, W.D.F., Clayden, P., and Serenata, C. The ADVANCE study: A groundbreaking trial to evaluate a candidate universal antiretroviral regimen. *Curr. Opin. HIV AIDS* **12**(4), 351-354 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/10/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM